Evidence map›Paper›PMID 42208544›Full record

Trial reportCell reports. Medicine2026

Pro/synbiotics reduce systemic inflammation and improve gut health in Kenyan infants: An open label, randomized, 4-arm, phase II trial.

Mary Iwaret Otiti, Micah June, Alloys K'Oloo, Miriam Chomba, James Dodd, Yutian Luo, Raymond Kiu, Lindsay Hall, Duolao Wang, Kephas Otieno and 3 more

Abstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mary Iwaret OtitiKenya Medical Research Institute (KEMRI), Centre for Global Health Research, Kisumu, Kenya.
Micah JuneKenya Medical Research Institute (KEMRI), Centre for Global Health Research, Kisumu, Kenya.
Alloys K'OlooKenya Medical Research Institute (KEMRI), Centre for Global Health Research, Kisumu, Kenya.
Miriam ChombaKenya Medical Research Institute (KEMRI), Centre for Global Health Research, Kisumu, Kenya.
James DoddGlobal Health Trials Unit, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Yutian LuoMailman School of Public Health, Columbia University Medical Center, New York, New York, USA.
Raymond KiuDepartment of Microbes, Infection and Microbiomes, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK; Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK; Food, Microbiome and Health, Quadram Institute Bioscience, Norwich Research Park, Norwich, UK.
Lindsay HallDepartment of Microbes, Infection and Microbiomes, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK; Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK; Food, Microbiome and Health, Quadram Institute Bioscience, Norwich Research Park, Norwich, UK; Norwich Medical School, University of East Anglia, Norwich, UK.
Duolao WangGlobal Health Trials Unit, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Kephas OtienoKenya Medical Research Institute (KEMRI), Centre for Global Health Research, Kisumu, Kenya.
Simon KariukiKenya Medical Research Institute (KEMRI), Centre for Global Health Research, Kisumu, Kenya.
Feiko O Ter KuileKenya Medical Research Institute (KEMRI), Centre for Global Health Research, Kisumu, Kenya; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Stephen AllenDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. Electronic address: stephen.allen@lstmed.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Environmental enteric dysfunction, universal in young children exposed to poor sanitation and hygiene, impairs growth and development through malabsorption and as a driver of chronic systemic inflammation (CSI). In an open-label, randomized, four-arm, phase II clinical trial, infants with birthweight ≥2000 g in Homa Bay County, western Kenya receive live, multi-strain Bifidobacterium spp. and Lactobacillaceae pro/synbiotics from 0 to 6 months. CSI (plasma α

Indexed as

Gastrointestinal MicrobiomeInflammationProbioticsSynbioticsBifidobacteriumFemaleHumansInfantInfant, NewbornKenyaMaleAfricabiomarkerchildrenclinical trialenvironmental enteric dysfunctiongrowth hormonesprobioticsynbioticsystemic inflammation

Identifiers

PMID42208544
PMCPMC13293936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.